Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06415175
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Prospective Observational Longitudinal Study in Paediatric Patients With AD Treated With Dupilumab in Spain
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROADAP
Brief Summary:
This is a multicentre prospective non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis AD patients aged 6 months to 11 years old in Spain patients characteristics disease characteristics prior treatments for and treatment prescription modalities As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up No diagnostic or therapeutic intervention outside of routine clinical practice will be applied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1306-7579 | REGISTRY | ICTRP | None |